Search
Ontuxizumab
go.drugbank.com/drugs/DB16270InvestigationalOntuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1).
Mevidalen
go.drugbank.com/drugs/DB19034InvestigationalMevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or
IDM-1
go.drugbank.com/drugs/DB05292ExperimentalIDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer.
D-Asparagine
go.drugbank.com/drugs/DB03943ExperimentalA non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase.
Glucose-6-Phosphate
go.drugbank.com/drugs/DB03581ExperimentalAn ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells.
(S)-Warfarin
go.drugbank.com/drugs/DB14055InvestigationalS-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A7166]
Bempegaldesleukin
go.drugbank.com/drugs/DB15140InvestigationalBempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy
Asundexian
go.drugbank.com/drugs/DB19088InvestigationalAsundexian is under investigation in clinical trial NCT05686070 (A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk
Razpipadon
go.drugbank.com/drugs/DB21542InvestigationalRazpipadon is under investigation in clinical trial NCT04958031 (A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy).
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-
go.drugbank.com/drugs/DB16204InvestigationalIsoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for the